The combination of talquetamab (Talvey) and daratumumab (Darzalex) demonstrated promising and robust clinical activity for the treatment of patients with heavily pretreated, relapsed/refractory ...
Iams, MD, MSCI, discussed potential ways to determine which patients benefit most from additional therapy for extensive-stage ...
The management of advanced thyroid cancer requires careful consideration of histology, molecular profiling, and treatment ...
While impressive efficacy was seen in both cohorts, Dr Strosberg reiterates the importance of a randomized study to confirm ...
The outlined treatment protocol involves a combination of systemic chemotherapy and peptide receptor radionuclide therapy ...
Lifileucel shows a 25.6% objective response rate and 71.8% disease control rate in advanced nonsquamous NSCLC patients, ...
Camizestrant combined with CDK4/6 inhibitors shows antitumor activity and is well-tolerated in ER+, HER2– advanced breast ...
The treatment landscape for high-risk myelodysplastic syndromes (HR MDS) is evolving, moving from supportive care toward a ...
1. Huang J. Disitamab vedotin plus tislelizumab as nephron-sparing therapy for high-risk upper tract urothelial carcinoma: The phase II DISTINCT-I trial. Presented at: ESMO 2025 Congress; October ...
Lutetium Lu 177 vipivotide tetraxetan combined with ARPI and ADT improved rPFS in PSMA-positive mHSPC patients compared to ARPI and ADT alone. Lutetium Lu 177 vipivotide tetraxetan significantly ...
The regimen of bexmarilimab and azacitidine (Vidaza) demonstrated a highly promising efficacy profile with a manageable ...
Vorasidenib significantly improved median progression-free survival and time to next intervention in IDH-mutant grade 2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback